Canaccord raised the firm’s price target on TransMedics (TMDX) to $148 from $147 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Positive Outlook for TransMedics Group: Buy Rating Justified by Aviation and Transplant Data Trends
- TransMedics price target raised to $166 from $148 at Needham
- TransMedics Group: Positive Trends in Flight and Organ Transplant Volumes Justify Buy Rating
- Positive Market Trends and TransMedics Aviation Drive Buy Rating for TransMedics Group
- TransMedics price target raised to $135 from $123 at Morgan Stanley